Cagrilintide / Tirzepatide

Tirzepatide Combination Therapy The Cagrilintide + Tirzepatide Combination represents a novel dual-pathway strategy for obesity and type 2 diabetes management. It integrates Cagrilintide, a long-acting amylin analog, with Tirzepatide, a dual GIP/GLP-1 receptor agonist, to deliver complementary appetite suppression, metabolic regulation, and glycemic control. Cagrilintide – synthetic amylin analog with ~ 184hour half-life. Activates amylin receptors (AMY 1R, AMY 3R) in the area postrema and dorsal vagal complex to enhance satiety, delay gastric emptying, and suppress postprandial glucagon. Tirzepatide – 39 – amino acid dual GIP/GLP-1 receptor agonist with ~ 5-day half-life. Increases glucose-dependent insulin secretion, inhibits glucagon, reduces appetite, improves insulin sensitivity, and enhances fat oxidation. The agents act on distinct but synergistic pathways: Cagrilintide regulates homeostatic feeding via brainstem mechanisms, while Tirzepatide influences hedonic appetite and systemic metabolism. Their matched pharmacokinetics enable once-weekly synchronized dosing.